ArticleCell reports. Medicine2023
An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions.
Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 25 citations in OpenAlex.
- Vectored Immunoprophylaxis for Mucosal Immunity: Advances and Challenges Associated with Recombinant Secretory IgA Expression.Vaccines · 2026Review
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- An RNA-to-RNA pipeline for rapid antiviral antibody development.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Human antibodies as emerging drugs for antimicrobial resistance.Trends in immunology · 2026Review
- Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice.NPJ vaccines · 2026Article
- mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.Biomolecules · 2026Review
- Maternal expression and breast milk transfer of an mRNA- encoded monoclonal antibody in a murine model of cholera.PLoS neglected tropical diseases · 2026Article
- Impaired mucosal IgA response to SARS-CoV-2 in patients with inborn errors of immunity.Frontiers in immunology · 2026Article
- Lipid nanoparticle-based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways.Archives of microbiology · 2025Review
- Nebulization of an mRNA-encoded monoclonal antibody for passive immunization of foals against Rhodococcus equi.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants.Nature microbiology · 2025Article
- Therapeutic Potential of Lipid Nanoparticle-Encapsulated CD19-Targeting mRNAs in Lupus and Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- AInfection and immunity · 2025Article
- Breast milk delivery of an engineered dimeric IgA protects neonates against rotavirus.Mucosal immunology · 2025Article
- Article
- Therapeutic antibody delivery: vector tools to boost efficacy and affordability.Frontiers in immunology · 2025Review
- Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates.Frontiers in immunology · 2025Article
- Health Benefits of Monk Fruit under Traditional Dietary Patterns: Perspective on Immunity and Gut Microbiota Modulatory Functions.Plant foods for human nutrition (Dordrecht, Netherlands) · 2024Article
- Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal transduction and targeted therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colonization of the gut and airways by pathogenic bacteria can lead to local tissue destruction and life-threatening systemic infections, especially in immunologically compromised individuals. Here, we describe an mRNA-based platform enabling delivery of pathogen-specific immunoglobulin A (IgA) monoclonal antibodies into mucosal secretions. The platform consists of synthetic mRNA encoding IgA heavy, light, and joining (J) chains, packaged in lipid nanoparticles (LNPs) that express glycosylated, dimeric IgA with functional activity in vitro and in vivo. Importantly, mRNA-derived IgA had a significantly greater serum half-life and a more native glycosylation profile in mice than did a recombinantly produced IgA. Expression of an mRNA encoded Salmonella-specific IgA in mice resulted in intestinal localization and limited Peyer's patch invasion. The same mRNA-LNP technology was used to express a Pseudomonas-specific IgA that protected from a lung challenge. Leveraging the mRNA antibody technology as a means to intercept bacterial pathogens at mucosal surfaces opens up avenues for prophylactic and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.